2 Top Biotech Stocks to Buy in December
These companies are carving their own paths in cellular medicine. One just posted promising clinical results, while the other aims to do so this month.
Editors' Picks
Is Alphabet's New CEO, Sundar Pichai, Ready for What's to Come?
Taking over for Google's founders, Pichai will be the one to navigate the company through an overdue rethinking of its business, for better or worse.
Why Investors Should Avoid Zscaler
The cybersecurity company reported strong fiscal first-quarter results and raised its guidance, but its stock price corresponds to higher expectations.
This Dividend-Paying Chip Stock Could Switch Up a Gear in 2020
Secular end-market growth should be a catalyst for chipmaker Analog Devices in the new year.
Recent articles
Why The Trade Desk Stock Popped 31.1% in November
The programmatic ad leader rallied after a positive quarterly report and the successful launch of Disney+.
Why Texas Capital Bancshares Jumped Today
The company is joining with a rival "to create the premier, Texas-based super regional bank."
Canopy Growth Stock Surges After the Company Names a New CEO
Investors cheered the cannabis company's choice for its new chief executive.
What Happened in the Stock Market Today
Two big deals for cancer drug companies made news today. Merck plans to buy ArQule and Sanofi will pay up to buy Synthorx.
Apple Dominates the Market as Wearables Shipments Surge
Recent shipments data from IDC shows that the iPhone maker's strategy is spot on.
Why International Flavors & Fragrances, Precision BioSciences, and GameStop Slumped Today
Find out why one of these stocks lost more than half its value.
Why Canopy Growth, PG&E, and Antero Midstream Jumped Today
Find out why these stocks stood out on a quiet day on Wall Street.
Why Express Shares Popped Today
Shares of the apparel retailer gained again on last week's earnings report.
This Small-Cap Biotech Gained as Much as 106.4% Today
XBiotech announced a massive deal with Johnson & Johnson subsidiary Janssen, which is thrusting the overlooked biopharma onto the radars of investors.
No CRISPR Required: This Forgotten Gene Editing Stock Is Up 50% in 5 Weeks
Investors should remember that CRISPR isn't the only gene editing technology out there. Case in point: ARCUS.
Why Nektar Therapeutics Stock Popped Today
Data presentations at a major scientific conference and the acquisition of another small biotech sparked investors' enthusiasm.
3 Stocks That Will Suffer in a Recession
Recessions and sell-offs are part and parcel of a free economy, but some companies are more exposed to the consequences of a downturn than others.
Thor Sharpens Its Profits While the North American Market Remains Soft
The RV giant is building a healthier margin profile as it waits for domestic demand to rebound.
Hardware Season Roundup: Big Tech's Not-So-Secret War
Though it may not garner the same publicity as software or streaming services, hardware is an integral part of these companies competing with one another.
Here's Why Shares of This Gene Editing Pioneer Are Collapsing Today
Precision BioSciences provided an expanded update from its first clinical asset. Investors weren't impressed.
Dow Jones News: Apple Faces Potential Tariffs; Intel Debuts Quantum Chip
Tariffs are coming for Apple, and Intel is working on scaling quantum computers.
Why 2U Stock Soared 39.1% in November
Activist investors and a new quarterly filing breathed life into 2U's battered stock.
Here's Why TG Therapeutics Rose as Much as 36.7% Today
A triple-combination therapy from the company triggered responses in 100% of patients with difficult-to-treat blood cancers.
If You Invested $10,000 in Guardant Health's IPO, This Is How Much Money You'd Have Now
This leading diagnostic company's stock has nearly quadrupled in value in just over one year.
Why Ubiquiti Stock Skyrocketed 55.8% in November
Another impressive quarterly report helped the networking products leader rally to a fresh all-time high.